These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1042 related items for PubMed ID: 10983647

  • 1. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1601-10. PubMed ID: 10983647
    [Abstract] [Full Text] [Related]

  • 2. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1591-600. PubMed ID: 10983646
    [Abstract] [Full Text] [Related]

  • 3. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB.
    AIDS; 2000 Jul 28; 14(11):1553-61. PubMed ID: 10983642
    [Abstract] [Full Text] [Related]

  • 4. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A, Chuah J, Hudson J, French M, Hoy J, Law M, Sayer D, Emery S, Cooper DA.
    AIDS; 2000 Jun 16; 14(9):1171-80. PubMed ID: 10894281
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P, Novavir Study Group.
    Antimicrob Agents Chemother; 2002 Jun 16; 46(6):1906-13. PubMed ID: 12019107
    [Abstract] [Full Text] [Related]

  • 6. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.
    AIDS; 1998 Aug 20; 12(12):1513-9. PubMed ID: 9727573
    [Abstract] [Full Text] [Related]

  • 7. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 8. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.
    Curr Med Res Opin; 2004 Jul 10; 20(7):1103-14. PubMed ID: 15265255
    [Abstract] [Full Text] [Related]

  • 9. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.
    AIDS; 1999 Apr 16; 13(6):685-94. PubMed ID: 10397563
    [Abstract] [Full Text] [Related]

  • 10. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team.
    JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744
    [Abstract] [Full Text] [Related]

  • 11. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
    Havlir DV, Gilbert PB, Bennett K, Collier AC, Hirsch MS, Tebas P, Adams EM, Wheat LJ, Goodwin D, Schnittman S, Holohan MK, Richman DD, ACTG 5025 Study Group.
    AIDS; 2001 Jul 27; 15(11):1379-88. PubMed ID: 11504959
    [Abstract] [Full Text] [Related]

  • 12. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.
    J Acquir Immune Defic Syndr; 2009 May 01; 51(1):37-46. PubMed ID: 19282782
    [Abstract] [Full Text] [Related]

  • 13. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM, Winters MA, Lawrence J, Merigan TC.
    AIDS; 1999 Feb 25; 13(3):359-65. PubMed ID: 10199226
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
    Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H.
    AIDS; 2000 Jun 16; 14(9):1181-5. PubMed ID: 10894282
    [Abstract] [Full Text] [Related]

  • 15. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
    Kumar PN, Rodriguez-French A, Thompson MA, Tashima KT, Averitt D, Wannamaker PG, Williams VC, Shaefer MS, Pakes GE, Pappa KA, ESS40002 Study Team.
    HIV Med; 2006 Mar 16; 7(2):85-98. PubMed ID: 16420253
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Mar 16; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
    Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK.
    HIV Med; 2002 Jan 16; 3(1):37-43. PubMed ID: 12059949
    [Abstract] [Full Text] [Related]

  • 18. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
    Phidisa II Writing Team for Project Phidisa, Ratsela A, Polis M, Dhlomo S, Emery S, Grandits G, Khabo P, Khanyile T, Komati S, Neaton JD, Naidoo LC, Magongoa D, Qolohle D.
    J Infect Dis; 2010 Nov 15; 202(10):1529-37. PubMed ID: 20942650
    [Abstract] [Full Text] [Related]

  • 19. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
    Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M, Lange J, Cooper DA, Phanuphak P.
    Antivir Ther; 2006 Nov 15; 11(2):223-32. PubMed ID: 16640103
    [Abstract] [Full Text] [Related]

  • 20. [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
    Geijo Martínez MP, Maciá Martínez MA, Solera Santos J, Barberá Farré JR, Rodríguez Zapata M, Marcos Sánchez F, Martínez Alfaro E, Cuadra García-Tenorio F, Sanz Moreno J, Moreno Mendaña JM, Beato Pérez JL, Sanz Sanz J, GECMEI.
    Rev Clin Esp; 2006 Feb 15; 206(2):67-76. PubMed ID: 16527165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.